Lantern Pharma is trading at $0.72, up 12.32%, with no confirmed company-specific catalyst identified for the move. - No new company-specific announcement was identified for October 20, 2026. - The LP-284 patent allowance was announced September 22 and is prior news, not a confirmed new catalyst. - The biotech sector is up 2.10%; sector strength, including attention around Merck’s agreement to acquire Silence Therapeutics, may be supportive context but does not confirm the cause.